Pathologic heterogeneity in clinically diagnosed corticobasal degeneration

Bradley F Boeve, D. M. Maraganore, Joseph E Parisi, J. E. Ahlskog, Neill R Graff Radford, Richard John Caselli, Dennis W Dickson, E. Kokmen, Ronald Carl Petersen

Research output: Contribution to journalArticle

309 Citations (Scopus)

Abstract

Background: Early reports suggested that corticobasal degeneration (CBD) is a distinct clinicopathologic entity. Because patients have had a fairly consistent constellation of clinical and laboratory findings, many have proposed that the pathologic diagnosis can be surmised with confidence during life. Objective: To analyze the pathologic findings in a large series of cases with clinically diagnosed CBD. Methods: Using the medical research linkage system of the Mayo Clinic for the period January 1990 to December 1997, we identified cases diagnosed during life with CBD who subsequently underwent autopsy. All patients had progressive asymmetric rigidity and apraxia (except one with rigidity but no apraxia) with other findings, suggesting additional cortical and basal ganglionic dysfunction. All cases underwent standardized neuropathologic examination with the distribution and severity of the pathologic changes determined for each case and the pathologic diagnoses based on currently accepted criteria. Results: Thirteen cases were identified. The pathologic diagnoses were CBD in seven, AD in two, and one each for progressive supranuclear palsy, Pick's disease, nonspecific degenerative changes, and Creutzfeldt-Jakob disease. Two cases had negligible basal ganglia and nigral degeneration despite previously having obvious extrapyramidal signs. However, all patients had focal or asymmetric cortical atrophy with coexisting neuronal loss and gliosis with or without status spongiosis, which was maximal in the parietal and frontal cortical regions. Conclusions: The constellation of clinical features considered characteristic of CBD is associated with heterogeneous pathologies. Furthermore, this syndrome can occur in the absence of basal ganglia and nigral degeneration. The one invariable pathologic abnormality in patients with this syndrome, however, is asymmetric parietofrontal cortical degeneration. At present, accurate diagnosis of CBD requires tissue examination.

Original languageEnglish (US)
Pages (from-to)795-800
Number of pages6
JournalNeurology
Volume53
Issue number4
StatePublished - Sep 11 1999

Fingerprint

Apraxias
Substantia Nigra
Basal Ganglia
Pick Disease of the Brain
Progressive Supranuclear Palsy
Creutzfeldt-Jakob Syndrome
Gliosis
Atrophy
Biomedical Research
Autopsy
Pathology

Keywords

  • Asymmetric cortical degeneration syndromes
  • Corticobasal degeneration
  • Neurodegenerative diseases
  • Neuronal achromasia

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. / Boeve, Bradley F; Maraganore, D. M.; Parisi, Joseph E; Ahlskog, J. E.; Graff Radford, Neill R; Caselli, Richard John; Dickson, Dennis W; Kokmen, E.; Petersen, Ronald Carl.

In: Neurology, Vol. 53, No. 4, 11.09.1999, p. 795-800.

Research output: Contribution to journalArticle

@article{30726fe396414feabb9716703ddc831f,
title = "Pathologic heterogeneity in clinically diagnosed corticobasal degeneration",
abstract = "Background: Early reports suggested that corticobasal degeneration (CBD) is a distinct clinicopathologic entity. Because patients have had a fairly consistent constellation of clinical and laboratory findings, many have proposed that the pathologic diagnosis can be surmised with confidence during life. Objective: To analyze the pathologic findings in a large series of cases with clinically diagnosed CBD. Methods: Using the medical research linkage system of the Mayo Clinic for the period January 1990 to December 1997, we identified cases diagnosed during life with CBD who subsequently underwent autopsy. All patients had progressive asymmetric rigidity and apraxia (except one with rigidity but no apraxia) with other findings, suggesting additional cortical and basal ganglionic dysfunction. All cases underwent standardized neuropathologic examination with the distribution and severity of the pathologic changes determined for each case and the pathologic diagnoses based on currently accepted criteria. Results: Thirteen cases were identified. The pathologic diagnoses were CBD in seven, AD in two, and one each for progressive supranuclear palsy, Pick's disease, nonspecific degenerative changes, and Creutzfeldt-Jakob disease. Two cases had negligible basal ganglia and nigral degeneration despite previously having obvious extrapyramidal signs. However, all patients had focal or asymmetric cortical atrophy with coexisting neuronal loss and gliosis with or without status spongiosis, which was maximal in the parietal and frontal cortical regions. Conclusions: The constellation of clinical features considered characteristic of CBD is associated with heterogeneous pathologies. Furthermore, this syndrome can occur in the absence of basal ganglia and nigral degeneration. The one invariable pathologic abnormality in patients with this syndrome, however, is asymmetric parietofrontal cortical degeneration. At present, accurate diagnosis of CBD requires tissue examination.",
keywords = "Asymmetric cortical degeneration syndromes, Corticobasal degeneration, Neurodegenerative diseases, Neuronal achromasia",
author = "Boeve, {Bradley F} and Maraganore, {D. M.} and Parisi, {Joseph E} and Ahlskog, {J. E.} and {Graff Radford}, {Neill R} and Caselli, {Richard John} and Dickson, {Dennis W} and E. Kokmen and Petersen, {Ronald Carl}",
year = "1999",
month = "9",
day = "11",
language = "English (US)",
volume = "53",
pages = "795--800",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Pathologic heterogeneity in clinically diagnosed corticobasal degeneration

AU - Boeve, Bradley F

AU - Maraganore, D. M.

AU - Parisi, Joseph E

AU - Ahlskog, J. E.

AU - Graff Radford, Neill R

AU - Caselli, Richard John

AU - Dickson, Dennis W

AU - Kokmen, E.

AU - Petersen, Ronald Carl

PY - 1999/9/11

Y1 - 1999/9/11

N2 - Background: Early reports suggested that corticobasal degeneration (CBD) is a distinct clinicopathologic entity. Because patients have had a fairly consistent constellation of clinical and laboratory findings, many have proposed that the pathologic diagnosis can be surmised with confidence during life. Objective: To analyze the pathologic findings in a large series of cases with clinically diagnosed CBD. Methods: Using the medical research linkage system of the Mayo Clinic for the period January 1990 to December 1997, we identified cases diagnosed during life with CBD who subsequently underwent autopsy. All patients had progressive asymmetric rigidity and apraxia (except one with rigidity but no apraxia) with other findings, suggesting additional cortical and basal ganglionic dysfunction. All cases underwent standardized neuropathologic examination with the distribution and severity of the pathologic changes determined for each case and the pathologic diagnoses based on currently accepted criteria. Results: Thirteen cases were identified. The pathologic diagnoses were CBD in seven, AD in two, and one each for progressive supranuclear palsy, Pick's disease, nonspecific degenerative changes, and Creutzfeldt-Jakob disease. Two cases had negligible basal ganglia and nigral degeneration despite previously having obvious extrapyramidal signs. However, all patients had focal or asymmetric cortical atrophy with coexisting neuronal loss and gliosis with or without status spongiosis, which was maximal in the parietal and frontal cortical regions. Conclusions: The constellation of clinical features considered characteristic of CBD is associated with heterogeneous pathologies. Furthermore, this syndrome can occur in the absence of basal ganglia and nigral degeneration. The one invariable pathologic abnormality in patients with this syndrome, however, is asymmetric parietofrontal cortical degeneration. At present, accurate diagnosis of CBD requires tissue examination.

AB - Background: Early reports suggested that corticobasal degeneration (CBD) is a distinct clinicopathologic entity. Because patients have had a fairly consistent constellation of clinical and laboratory findings, many have proposed that the pathologic diagnosis can be surmised with confidence during life. Objective: To analyze the pathologic findings in a large series of cases with clinically diagnosed CBD. Methods: Using the medical research linkage system of the Mayo Clinic for the period January 1990 to December 1997, we identified cases diagnosed during life with CBD who subsequently underwent autopsy. All patients had progressive asymmetric rigidity and apraxia (except one with rigidity but no apraxia) with other findings, suggesting additional cortical and basal ganglionic dysfunction. All cases underwent standardized neuropathologic examination with the distribution and severity of the pathologic changes determined for each case and the pathologic diagnoses based on currently accepted criteria. Results: Thirteen cases were identified. The pathologic diagnoses were CBD in seven, AD in two, and one each for progressive supranuclear palsy, Pick's disease, nonspecific degenerative changes, and Creutzfeldt-Jakob disease. Two cases had negligible basal ganglia and nigral degeneration despite previously having obvious extrapyramidal signs. However, all patients had focal or asymmetric cortical atrophy with coexisting neuronal loss and gliosis with or without status spongiosis, which was maximal in the parietal and frontal cortical regions. Conclusions: The constellation of clinical features considered characteristic of CBD is associated with heterogeneous pathologies. Furthermore, this syndrome can occur in the absence of basal ganglia and nigral degeneration. The one invariable pathologic abnormality in patients with this syndrome, however, is asymmetric parietofrontal cortical degeneration. At present, accurate diagnosis of CBD requires tissue examination.

KW - Asymmetric cortical degeneration syndromes

KW - Corticobasal degeneration

KW - Neurodegenerative diseases

KW - Neuronal achromasia

UR - http://www.scopus.com/inward/record.url?scp=0033546981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033546981&partnerID=8YFLogxK

M3 - Article

C2 - 10489043

AN - SCOPUS:0033546981

VL - 53

SP - 795

EP - 800

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 4

ER -